Denmark's cardiovascular system medicine sales in 2024 are forecasted to stand at 21.9 USD per capita, reflecting the data obtained for the period from 2024 to 2028, with sales expected to steadily decline year-on-year. By 2025, this figure is anticipated to drop to 20.5 USD per capita, indicating a year-on-year decrease of approximately 6.4%. This decline continues through to 2028, where the projected sales per capita are 17.8 USD, marking an overall compound annual growth rate (CAGR) of about -5.0% over the five-year period.

Trends to watch:

Monitor changing healthcare policies and regulations which might impact medication pricing and accessibility.
Advancements in cardiovascular treatment options that could alter market dynamics.
Shifts in demographic patterns, such as aging population, which could influence the demand for cardiovascular treatments.
Impact of new entrants and innovations in the pharmaceutical industry on market competitiveness.